DOC Updates14 Jan 2025

Special Edition - Diabetes Core Update - CGM - January 2025

Welcome to this special edition of Diabetes Core Update, where host Dr. Neil Skolnik takes a deep dive into the transformative role of continuous glucose monitoring (CGM) in diabetes care. Through engaging conversations with two leading experts, Dr. Skolnik explores the latest advancements in CGM technology, its clinical benefits, and its growing accessibility. Packed with valuable insights, this episode is an essential listen for healthcare professionals navigating the evolving landscape of diabetes management.

This episode is sponsored by Dexcom, the #1 HCP-recommended CGM brand* and creators of Dexcom G7.

Presented by:

Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Eden Miller, DO, Founder of Diabetes Nation, a nonprofit organization, and CEO of Diabetes and Obesity Care, Bend, Oregon

Eugene Wright, MD, Medical Director of Performance Improvement, Charlotte Area Health Education Center, Charlotte, North Carolina; Consulting Associate, Department of Medicine, Duke University Medical Center, Durham, North Carolina

Select resources and studies mentioned in the podcast:

https://pro.diabeteswise.org/en/resources

https://www.aafp.org/pubs/fpm/issues/2024/0100/continuous-glucose-monitoring.pdf

https://www.adces.org/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/cgm-insurance-coverage-look-up

Miller E, Chuang JS, Roberts GJ, Nabutovsky Y, Virdi N, Wright Jr. EE: Association of changes in A1C following continuous glucose monitoring acquisition in people with sub‐optimally treated type 2 diabetes taking GLP‐1 RA therapy. Diabetes Therapy 2024;15:2027-2038 https://doi.org/10.1007/s13300-024-01619-1

This special episode of Diabetes Core Update is sponsored by Dexcom, the #1 HCP-recommended CGM brand* and creators of Dexcom G7 (1). Dexcom G7 is a continuous glucose monitoring system, designed for patients with all types of diabetes (2). The American Diabetes Association recommends the use of CGM in people with diabetes, as CGM is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range (3).

Getting started with Dexcom G7 is easy, with only one prescription needed. Visit https://Dexcom.com/ADA for prescribing information and to sample Dexcom G7 for free.

*Based on a comparison in NPS scores across major CGM brands.

References

1. Seagrove Partners, LLC. Seagrove Partners HCP Perspectives. 2022

2. Dexcom. Dexcom G7 User Guide. 2023

3. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl. 1):S1–S352

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(100)

Beyond Diabetes and Obesity: Expanding Applications of Incretin Biology

You know how GLP-1s impact diabetes and weight loss. But what about coronary disease treatment and prevention? Liver disease? Heart failure? Osteoarthritis? Sleep apnea? In this special episode, Dr. N...

6 Okt 32min

T2D & Bone Density, Microarchitecture, & Strength; Early Weight Loss, Glucose Tolerance, & Long-Term Mortality/CVD Risk; and more!

Welcome to the latest episode (October 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic diseas...

24 Sep 32min

Sarcopenic Obesity & T2D, Cumulative BMI Burden From Childhood to Adulthood & Risk of Metabolic Multimorbidity, and more!

Welcome to the latest episode (September 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic dise...

14 Sep 24min

Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone

Uncontrolled and resistant hypertension is more common than we think. In the second episode of this special three-part series, Dr. Neil Skolnik discusses management strategies, but also explores our n...

8 Sep 39min

Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)

What is the difference between MASH and MASLD? In this special episode, Dr. Neil Skolnik breaks down these conditions, which affect insulin resistance of the liver, an area of increasing concern for p...

3 Sep 22min

Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance

Weight maintenance is a challenging topic for both clinicians and patients. In this special episode, Neil Skolnik is joined by Jamie Almondoz, MD, who discusses the toxic narratives that have historic...

24 Aug 32min

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates ...

17 Aug 33min

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE...

10 Aug 35min